---
layout: post
title: "Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:56:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-19796
original_published: 2023-09-13 00:00:00 +0000
significance: 8.00
---

# Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 13, 2023 00:00 UTC
**Document Number:** 2023-19796

## Summary

The Food and Drug Administration (FDA, Agency, or we) has determined that Oxandrin (oxandrolone) tablets, 2.5 milligrams (mg) and 10 mg, were withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve abbreviated new drug applications (ANDAs) for Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/13/2023-19796/determination-that-oxandrin-oxandrolone-tablets-25-milligrams-and-10-milligrams-were-withdrawn-from)
- API: https://www.federalregister.gov/api/v1/documents/2023-19796

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
